Skip to content

FAQs

Discover the answers to some frequently asked questions.

What is spinal cord stimulation?
Spinal cord stimulation, also called neurostimulation or neuromodulation, is a medical therapy that sends electrical signals to select areas of the spinal cord.
What is spinal cord injury?
Spinal cord injury, or SCI, is a devastating condition that affects millions of people worldwide, leading to partial or complete loss of motor and sensory functions.
What is ARC Therapy?
ARC Therapy is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury.
What is ARCEX?
ARCEX is an FDA-cleared, spinal cord stimulation system that targets areas of injury on the spinal cord with programmed electrical pulses through the skin. The ARCEX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Cleared for use only in the United States.
What is ARCIM?
ARCIM is an investigational spinal cord stimulation system, which includes an implantable Neurostimulator that generates electrical pulses that are programmed to target areas of injury on the spinal cord. The system is designed to improve functional recovery of strength, function, and movement after spinal cord injury.
When and where will these therapies be available?
We are working hard to conduct the clinical studies required for regulatory approval of our therapies in the US and Europe, as well as other countries in the future.
What is the evidence behind ARC Therapy?
The benefits of ONWARD ARC Therapy have been observed in published pre-clinical and human feasibility studies. A human pivotal clinical study has been completed, called Up-LIFT, designed to evaluate the safety and effectiveness of our ARCEX Therapy to improve upper limb mobility. Learn more about it on the External ARCEX page. Clinical results may vary.
What is the evidence behind ARCEX Therapy?
Positive results of the Up-LIFT pivotal trial were published in Nature Medicine in May of 2024. Visit the External ARCEX page to learn more. Clinical results may vary.
The ONWARD® Medical ARCEX® System is FDA cleared for use in the United States and CE marked in accordance with EU Medical Device Regulation 2017/745. ONWARD ARCIM® and ARCBCI™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

Indication for Use (US): The ARCEX® System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old who present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

Indication for Use (EU): The ARCEX® System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).